CA2623957A1 - Compositions for and methods of granzyme b inhibition - Google Patents

Compositions for and methods of granzyme b inhibition Download PDF

Info

Publication number
CA2623957A1
CA2623957A1 CA002623957A CA2623957A CA2623957A1 CA 2623957 A1 CA2623957 A1 CA 2623957A1 CA 002623957 A CA002623957 A CA 002623957A CA 2623957 A CA2623957 A CA 2623957A CA 2623957 A1 CA2623957 A1 CA 2623957A1
Authority
CA
Canada
Prior art keywords
granzyme
cell
cells
serpin
serpina3n
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002623957A
Other languages
English (en)
French (fr)
Inventor
Ray V. Rajotte
R. Chris Bleackley
Gregory Korbutt
Sarah J. Lord
Simonetta Sipione
Katia Carmine-Simmen
Fabrizio Giuliani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Alberta
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2623957A1 publication Critical patent/CA2623957A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8121—Serpins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/39—Pancreas; Islets of Langerhans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6467—Granzymes, e.g. granzyme A (3.4.21.78); granzyme B (3.4.21.79)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/108—Swine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/40—Fish
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • A01K2267/025—Animal producing cells or organs for transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Environmental Sciences (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Animal Husbandry (AREA)
  • Nutrition Science (AREA)
  • Vascular Medicine (AREA)
  • Plant Pathology (AREA)
CA002623957A 2005-09-29 2006-09-26 Compositions for and methods of granzyme b inhibition Abandoned CA2623957A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US72179905P 2005-09-29 2005-09-29
US60/721,799 2005-09-29
PCT/CA2006/001582 WO2007036028A1 (en) 2005-09-29 2006-09-26 Compositions for and methods of granzyme b inhibition

Publications (1)

Publication Number Publication Date
CA2623957A1 true CA2623957A1 (en) 2007-04-05

Family

ID=37899312

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002623957A Abandoned CA2623957A1 (en) 2005-09-29 2006-09-26 Compositions for and methods of granzyme b inhibition

Country Status (6)

Country Link
US (2) US20070104699A1 (enExample)
EP (1) EP1940458A4 (enExample)
JP (1) JP2009509979A (enExample)
AU (1) AU2006297036A1 (enExample)
CA (1) CA2623957A1 (enExample)
WO (1) WO2007036028A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7951776B2 (en) * 2006-09-01 2011-05-31 American Type Culture Collection Methods for treatment of type 1 diabetes
CA2739523A1 (en) * 2007-10-01 2009-04-09 The University Of British Columbia Treatment of dissection, aneurysm, and atherosclerosis using granzyme b inhibitors
US8426149B2 (en) 2007-10-01 2013-04-23 The University Of British Columbia Granzyme A and granzyme B diagnostics
JP6134268B2 (ja) * 2010-12-06 2017-05-24 ザ ユニバーシティ オブ ブリティッシュ コロンビア 創傷治癒を促進するためのグランザイムｂ阻害剤組成物、方法および使用
JP7194595B2 (ja) 2016-07-01 2022-12-22 ザ ジェネラル ホスピタル コーポレイション グランザイムｂを指向するイメージングおよび治療
CN119345374A (zh) * 2024-10-31 2025-01-24 南通大学 靶向颗粒酶b在帕金森病神经元退变免疫治疗药物中的应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674708A (en) * 1989-06-23 1997-10-07 Trustees Of The University Of Pennsylvania α-1-antichymotrypsin analogues having elastase inhibitory activity
US5612194A (en) * 1989-06-23 1997-03-18 Trustees Of The University Of Pennsylvania Methods of producing effective recombinant serine protease inhibitors and uses of these inhibitors
US5266465A (en) * 1989-06-23 1993-11-30 The Trustees Of The University Of Pennsylvania α-1-antichymotrypsin, analogues and methods of production
DE10121255A1 (de) * 2001-04-30 2002-11-07 Switch Biotech Ag Verwendung von alpha 1-Antichymotrypsin Polypeptiden oder diese kodierende Nukleinsäuren, oder einer ein ACT Polypeptid oder diese kodierende Nukleinsäure exprimierende Zelle, zur Behandlung und/oder Prävention von diabetes-assoziierten und/oder arteriellen schlecht heilenden Wunden und zur Identifizierung von pharmakologisch aktiven Substanzen
WO2003065987A2 (en) * 2002-02-04 2003-08-14 Merck & Co., Inc. Granzyme b inhibitors
AU2003275173A1 (en) * 2002-09-25 2004-04-19 Board Of Regents, The University Of Texas System Endogenous granzyme b in human non-hematopoietic cells
JP2005120070A (ja) * 2003-03-10 2005-05-12 Taisho Pharmaceut Co Ltd エラスターゼ遊離抑制剤及び脳梗塞治療薬
US20070116694A1 (en) * 2003-06-18 2007-05-24 Daiichi Pharmaceutical Co., Ltd. Inhibitor of interaction of granzyme b with golgin-160
JP2005060379A (ja) * 2003-07-31 2005-03-10 Dainippon Pharmaceut Co Ltd 複素環式化合物からなる医薬
SE0302487D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
EP1879448A2 (en) * 2005-02-25 2008-01-23 University of Chicago Compositions and methods related to serpin spi6

Also Published As

Publication number Publication date
EP1940458A1 (en) 2008-07-09
WO2007036028A9 (en) 2007-07-05
JP2009509979A (ja) 2009-03-12
EP1940458A4 (en) 2010-03-03
AU2006297036A1 (en) 2007-04-05
US20110083201A1 (en) 2011-04-07
US20070104699A1 (en) 2007-05-10
WO2007036028A1 (en) 2007-04-05

Similar Documents

Publication Publication Date Title
JP7751607B2 (ja) 膵機能障害の治療または予防方法
DK1753456T3 (en) METHODS OF TREATING CONDITIONS CONNECTED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION
EP2741757B1 (en) Compositions of functional mitochondria and uses thereof
ES2516690T5 (es) Inhibidores de la actividad de serina proteasa y su uso en métodos y composiciones para el tratamiento de rechazo de injertos y promoción de supervivencia de injertos
US20110083201A1 (en) Compositions for and methods of grazyme b inhibition
EA013821B1 (ru) Проостровковые пептиды человека, их производные и аналоги и способы их применения
KR20140102730A (ko) 포유류 태아 폐 세포와 이를 치료용으로 사용하는 방법
Baligar et al. Bone marrow stem cell therapy partially ameliorates pathological consequences in livers of mice expressing mutant human α1‐antitrypsin
JP2007527712A (ja) 新規な遺伝子破壊、これに関する組成物と方法
CA2611002A1 (en) Stimulation of pancreatic .beta. cell proliferation
KR20150140686A (ko) 신증후군 및 관련 병태의 치료 방법
KR101658163B1 (ko) 만능 줄기세포-유래의 테라토마 형성 억제방법
US20100210713A1 (en) Regeneration and survival of cardiac progenitors and cardiomyocytes with a stretch activated transcription factor
US20060275274A1 (en) Use of saposin-related proteins for preventing and treating obesity, diabetes and/or metabolic syndrome
US12371666B2 (en) Nucleoside modified mRNA and uses thereof
US7074911B2 (en) Endogenous granzyme B in non-immune cells
KR102293673B1 (ko) 세룰로플라스민 유래 펩타이드 및 이를 포함하는 부화 촉진용 조성물
JP5025173B2 (ja) ヒト肝細胞を有するマウスの処置方法
WO2005046718A1 (en) Diagnosis and hyperinsulinemia and type ii diabetes and protection against same based on genes differentially expressed in pancreas cells (12.1)
Lo The Role of Serpin B13 Antibody in Regeneration of Pancreatic β-Cells
Bleackley et al. Identification of a Novel Human Granzyme B
Huang Neonatal Pig as an Alternative Source of Islets for Transplantation
DE60034036T2 (de) Verfahren und zusammensetzungen zur inhibierung des neoplastischen zellwachstums
Shrivastava The Role of Prolactin Receptors in Regulation of Pancreatic Beta Cell Mass and Function
Wideman Manipulating proglucagon processing in the pancreatic alpha-cell for the treatment of diabetes

Legal Events

Date Code Title Description
FZDE Discontinued